DBV Technologies Stock Rises 2.85% to €3.54 Ahead of Two FDA Filings in 2026
French biotech company advances 2.85% to €3.54 in mid-morning trading, alongside a 1.58% increase in the CAC 40. The stock is trading close to its 50-day moving average and remains well above its 200-day moving average at €2.80. The year 2026 is set to be pivotal in terms of regulatory developments for its anti-allergen patch, Viaskin Peanut.
DBV Technologies' schedule is marked by upcoming U.S. regulatory deadlines. The biotech has confirmed its plans to submit two Biologics License Applications this year to the FDA, one for children aged 4 to 7, and another for toddlers aged 1 to 3, as reiterated in its early May communication. The company also plans to initiate a Phase 2 study in infants aged 6 to 12 months. Financially, the company reported a cash position of $229 million as of March 31, 2026, following the full exercise of warrants from the private placement in March 2025. This funding is expected to cover expenses until the second quarter of 2027, according to the company's published documents. The net loss for the first quarter widened to $47.6 million, reflecting increased R&D spending in preparation for regulatory submissions. The next key date on the calendar is the Mixed General Meeting on June 3.
Stock Price Caught Between 50-Day MA and €3.85 Resistance
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock is trading at €3.54, just below its 50-day moving average of €3.60. Crossing this short-term benchmark is necessary to reignite momentum towards the resistance level at €3.85, which represents an approximate 8.8% increase from the current price. The 200-day moving average at €2.80 remains significantly lower, indicating that the long-term trend is still bullish with an annual performance of 121.6%. The RSI at 46 indicates a lack of directional momentum following a 7.8% decline over three months. The next important date for shareholders is the General Meeting on June 3, 2026.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
